Product Description
Linagliptin (Trajenta(®), Tradjenta(®)) is a dipeptidyl peptidase (DPP)-4 inhibitor approved for the treatment of adults with type 2 diabetes mellitus in several countries. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25297911/)
Mechanisms of Action: DPP4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Pancreatitis | Type 1 Diabetes | General Diabetes | Type 2 Diabetes | Pancreatitis | Type 1 Diabetes | General Diabetes | Type 2 Diabetes | Pancreatitis | Type 1 Diabetes | Acidosis | Diabetic Ketoacidosis | General Diabetes | Type 2 Diabetes | Pancreatitis | Type 1 Diabetes | Acidosis | Diabetic Ketoacidosis | General Diabetes | Type 2 Diabetes
Known Adverse Events: Nasopharyngitis | Pharyngitis | Diarrhea | Headache | Enteritis | Gastroenteritis | Respiratory Tract Infections | Constipation | Urinary Tract Infections
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Linagliptin](https://pryzm-maps.s3.us-west-2.amazonaws.com/575current_maps.png)
Countries in Clinic: Argentina, Australia, Brazil, Canada, China, Colombia, Germany, Israel, Korea, Mexico, Puerto Rico, Russia, Thailand, United Kingdom, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Type 2 Diabetes
Phase 1: Healthy Volunteers|Idiopathic Pulmonary Fibrosis|Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
DW6013-I-2 | P1 |
Completed |
Healthy Volunteers |
2023-02-01 |
28% |
DINAMO | P3 |
Completed |
Type 2 Diabetes |
2022-10-19 |
|
DW6013-I-1 | P1 |
Completed |
Healthy Volunteers |
2022-10-11 |
28% |
2016-000669-21 | P3 |
Active, not recruiting |
Type 2 Diabetes |
2022-04-02 |